Pfizer To Initiate Late-stage Study Of ALK Inhibitor In Cancer Patients With Specific Gene Mutation – Update
September 24th, 2009
Thursday, pharma major Pfizer Inc. said that it will initiate a global, Phase 3 clinical trial of PF-02341066, its investigational oral c-Met and ALK inhibitor, being developed to treat patients with advanced non-small cell lung cancer, or NSCLC, who also carry the anaplastic lymphoma kinases, or ALK, fusion gene and who have progressed on one prior treatment with a platinum-based chemotherapy.